<p>New Delhi: Jubilant Pharmova Ltd on Friday reported a consolidated net profit of Rs 151.3 crore in the fourth quarter ended March 31, 2025.</p>.<p>The company had posted a consolidated net loss of Rs 61.8 crore in the same quarter previous fiscal, Jubilant Pharmova Ltd said in a regulatory filing.</p>.<p>Consolidated total revenue from operations stood at Rs 1,928.8 crore as against Rs 1,758.6 crore in the year-ago period, it added.</p>.India's GDP growth revised downward to 6.3% for 2025, country remains one of fastest-growing large economies: UN.<p>Total expenses in the fourth quarter were higher at Rs 1,731.3 crore as compared to Rs 1,661.2 crore in the same period a year ago.</p>.<p>In the fiscal ended March 31, 2025, consolidated net profit was Rs 836.3 crore as against Rs 72.7 crore in FY24.</p>.<p>In FY25, consolidated total revenue from operations stood at Rs 7,234.5 crore as compared to Rs 6,702.9 crore in the preceding year, the company said.</p>.<p>The board of directors have recommended a final dividend of Rs 5 per equity share of Re 1 each for the financial year ended March 31, 2025, the filing said. </p>
<p>New Delhi: Jubilant Pharmova Ltd on Friday reported a consolidated net profit of Rs 151.3 crore in the fourth quarter ended March 31, 2025.</p>.<p>The company had posted a consolidated net loss of Rs 61.8 crore in the same quarter previous fiscal, Jubilant Pharmova Ltd said in a regulatory filing.</p>.<p>Consolidated total revenue from operations stood at Rs 1,928.8 crore as against Rs 1,758.6 crore in the year-ago period, it added.</p>.India's GDP growth revised downward to 6.3% for 2025, country remains one of fastest-growing large economies: UN.<p>Total expenses in the fourth quarter were higher at Rs 1,731.3 crore as compared to Rs 1,661.2 crore in the same period a year ago.</p>.<p>In the fiscal ended March 31, 2025, consolidated net profit was Rs 836.3 crore as against Rs 72.7 crore in FY24.</p>.<p>In FY25, consolidated total revenue from operations stood at Rs 7,234.5 crore as compared to Rs 6,702.9 crore in the preceding year, the company said.</p>.<p>The board of directors have recommended a final dividend of Rs 5 per equity share of Re 1 each for the financial year ended March 31, 2025, the filing said. </p>